Valuation: ViroGates A/S

Market Cap 93.75M 14.29M 12.54M 11.85M 10.79M 20.21M 1.37B 20.35M 142M 54.9M 700M 53.66M 52.5M 2.25B P/E 2024
-4.92x
P/E 2025 -10.2x
Enterprise Value 72.07M 10.99M 9.64M 9.11M 8.3M 15.54M 1.05B 15.65M 109M 42.21M 538M 41.26M 40.36M 1.73B EV / Sales 2024
10.5x
EV / Sales 2025 11.6x
Free-Float
25.48%
Yield 2024 *
-
Yield 2025 -
1 day-0.98%
Current month-3.81%
1 month+2.02%
3 months-0.98%
6 months-9.42%
Current year-24.91%
1 week 10
Extreme 10
10.3
1 month 9.8
Extreme 9.8
12
Current year 9.05
Extreme 9.05
14
1 year 9.05
Extreme 9.05
17.4
3 years 4.98
Extreme 4.98
31
5 years 4.98
Extreme 4.98
188
10 years 4.98
Extreme 4.98
252
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 31/12/2000
Chief Executive Officer 58 31/03/2011
Director of Finance/CFO 35 28/02/2023
Director TitleAgeSince
Chairman 65 31/01/2015
Chairman 64 30/04/2022
Director/Board Member 59 31/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%0.00%+1.00%-51.67% 14.29M
+1.85%+7.32%+444.55%+140.70% 4.98B
-0.47%+2.87%+124.14%+479.33% 4.7B
-6.41%+14.16%+38.42%+102.18% 3.65B
+3.76%+18.30%+328.24%+733.51% 3.29B
+2.50%+13.65%-9.00%-15.09% 2.58B
-4.59%-8.24%+48.11% - 1.72B
-0.58%+0.59%+34.12%+63.46% 1.14B
-0.65%+9.04%+182.53%-18.28% 1.13B
+5.08%+8.18%-25.64%+125.45% 629M
Average -0.09%+6.66%+116.65%+173.29% 2.38B
Weighted average by Cap. -0.25%+8.59%+180.73%+263.68%

Financials

2024 2025
Net sales 7.14M 1.09M 955K 902K 822K 1.54M 104M 1.55M 10.8M 4.18M 53.32M 4.09M 4M 171M 8.9M 1.36M 1.19M 1.13M 1.03M 1.92M 130M 1.93M 13.46M 5.21M 66.47M 5.1M 4.99M 214M
Net income -14.34M -2.19M -1.92M -1.81M -1.65M -3.09M -210M -3.11M -21.69M -8.4M -107M -8.21M -8.03M -344M -10.4M -1.59M -1.39M -1.31M -1.2M -2.24M -152M -2.26M -15.72M -6.09M -77.61M -5.95M -5.82M -249M
Net Debt -6.91M -1.05M -924K -873K -795K -1.49M -101M -1.5M -10.44M -4.05M -51.57M -3.95M -3.87M -166M -21.67M -3.3M -2.9M -2.74M -2.5M -4.67M -317M -4.71M -32.77M -12.69M -162M -12.41M -12.14M -520M
Logo ViroGates A/S
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Employees
7
Date Price Change Volume
25/09/26 DKK 10.10 -0.98% 33
24/09/26 DKK 10.20 +2.00% 5
23/09/26 DKK 10.00 -0.99% 457
22/09/26 DKK 10.10 -1.94% 1,091
21/09/26 DKK 10.30 +1.98% 1

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIRO Stock